# Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.

> **NCT02824354** · PHASE3 · WITHDRAWN · sponsor: **Centre Hospitalier Universitaire, Amiens**

## Conditions studied

- Cirrhosis
- Alcohol Dependence
- Nalmefene

## Interventions

- **DRUG:** Nalmefene (Selincro®) 18 mg tablet
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02824354
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no participants enrolled
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824354, "Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02824354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*